Endoscopic Treatment of Vesicoureteral Reflux with Dextranomer/Hyaluronic Acid in Children

Purpose. The goal of this review is to present current indications, injectable agents, techniques, success rates, complications, and potential future applications of endoscopic treatment for vesicoureteral reflux (VUR) in children. Materials and Methods. The endoscopic method currently achieving one...

Full description

Saved in:
Bibliographic Details
Main Authors: Wolfgang H. Cerwinka, Hal C. Scherz, Andrew J. Kirsch
Format: Article
Language:English
Published: Wiley 2008-01-01
Series:Advances in Urology
Online Access:http://dx.doi.org/10.1155/2008/513854
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849696125749035008
author Wolfgang H. Cerwinka
Hal C. Scherz
Andrew J. Kirsch
author_facet Wolfgang H. Cerwinka
Hal C. Scherz
Andrew J. Kirsch
author_sort Wolfgang H. Cerwinka
collection DOAJ
description Purpose. The goal of this review is to present current indications, injectable agents, techniques, success rates, complications, and potential future applications of endoscopic treatment for vesicoureteral reflux (VUR) in children. Materials and Methods. The endoscopic method currently achieving one of the highest success rates is the double hydrodistention-implantation technique (HIT). This method employs dextranomer/hyaluronic acid copolymer, which has been used in pediatric urology for over 10 years and may be at present the first choice injectable agent due to its safety and efficacy. Results. While most contemporary series report cure rates of greater than 85% for primary VUR, success rates of complicated cases of VUR may be, depending on the case, significantly lower. Endoscopic treatment offers major advantages to patients while avoiding potentially complicated open surgery. As the HIT method continues to be applied to complex cases of VUR and more outcome data become available, the indication for endoscopic treatment may exceed the scope of primary VUR. Conclusions. Endoscopic injection is emerging as the treatment of choice for VUR in children.
format Article
id doaj-art-d598b39e2e9b4e5bad404cf0896f0e3a
institution DOAJ
issn 1687-6369
1687-6377
language English
publishDate 2008-01-01
publisher Wiley
record_format Article
series Advances in Urology
spelling doaj-art-d598b39e2e9b4e5bad404cf0896f0e3a2025-08-20T03:19:33ZengWileyAdvances in Urology1687-63691687-63772008-01-01200810.1155/2008/513854513854Endoscopic Treatment of Vesicoureteral Reflux with Dextranomer/Hyaluronic Acid in ChildrenWolfgang H. Cerwinka0Hal C. Scherz1Andrew J. Kirsch2Children's Healthcare of Atlanta, Emory University School of Medicine, 5445 Meridian Mark Road, Suite 420, Atlanta, GA 30342, USAChildren's Healthcare of Atlanta, Emory University School of Medicine, 5445 Meridian Mark Road, Suite 420, Atlanta, GA 30342, USAChildren's Healthcare of Atlanta, Emory University School of Medicine, 5445 Meridian Mark Road, Suite 420, Atlanta, GA 30342, USAPurpose. The goal of this review is to present current indications, injectable agents, techniques, success rates, complications, and potential future applications of endoscopic treatment for vesicoureteral reflux (VUR) in children. Materials and Methods. The endoscopic method currently achieving one of the highest success rates is the double hydrodistention-implantation technique (HIT). This method employs dextranomer/hyaluronic acid copolymer, which has been used in pediatric urology for over 10 years and may be at present the first choice injectable agent due to its safety and efficacy. Results. While most contemporary series report cure rates of greater than 85% for primary VUR, success rates of complicated cases of VUR may be, depending on the case, significantly lower. Endoscopic treatment offers major advantages to patients while avoiding potentially complicated open surgery. As the HIT method continues to be applied to complex cases of VUR and more outcome data become available, the indication for endoscopic treatment may exceed the scope of primary VUR. Conclusions. Endoscopic injection is emerging as the treatment of choice for VUR in children.http://dx.doi.org/10.1155/2008/513854
spellingShingle Wolfgang H. Cerwinka
Hal C. Scherz
Andrew J. Kirsch
Endoscopic Treatment of Vesicoureteral Reflux with Dextranomer/Hyaluronic Acid in Children
Advances in Urology
title Endoscopic Treatment of Vesicoureteral Reflux with Dextranomer/Hyaluronic Acid in Children
title_full Endoscopic Treatment of Vesicoureteral Reflux with Dextranomer/Hyaluronic Acid in Children
title_fullStr Endoscopic Treatment of Vesicoureteral Reflux with Dextranomer/Hyaluronic Acid in Children
title_full_unstemmed Endoscopic Treatment of Vesicoureteral Reflux with Dextranomer/Hyaluronic Acid in Children
title_short Endoscopic Treatment of Vesicoureteral Reflux with Dextranomer/Hyaluronic Acid in Children
title_sort endoscopic treatment of vesicoureteral reflux with dextranomer hyaluronic acid in children
url http://dx.doi.org/10.1155/2008/513854
work_keys_str_mv AT wolfganghcerwinka endoscopictreatmentofvesicoureteralrefluxwithdextranomerhyaluronicacidinchildren
AT halcscherz endoscopictreatmentofvesicoureteralrefluxwithdextranomerhyaluronicacidinchildren
AT andrewjkirsch endoscopictreatmentofvesicoureteralrefluxwithdextranomerhyaluronicacidinchildren